[Progress in the development of vaccines against Aujeszky's disease]
- PMID: 8585074
[Progress in the development of vaccines against Aujeszky's disease]
Abstract
New insights into the molecular biology of pseudorabies virus (PrV), the causative agent of Aujeszky's disease (AD) of pigs, led to novel concepts for eradication of the disease. Virus mutants, which lack certain nonessential glycoproteins, formed the basis for the development of the first available marked vaccines. They allow a differentiation between infected and vaccinated animals. Further molecular studies resulted in the identification of several PrV genes whose products modulate virulence and pathogenicity of the virus, and which are therefore targeted by genetic engineering methods to develop new attenuated virus strains. The isolation of virus mutants, which cannot be shed in infectious form by vaccinated animals, led to an increase in the biological safety of respective PrV vaccines. The availability of these mutants now provides the basis for the development of safe PrV vector vaccines, in which recombinant PrV express immunogenic proteins of other, unrelated viruses leading to a broad antiviral immunity. Based on PrV vectors marked vaccines against other viral diseases are being developed which represent powerful tools for combatting infectious diseases in animals.
Similar articles
-
Pseudorabies (Aujeszky's disease) virus: state of the art. August 1993.Acta Vet Hung. 1994;42(2-3):153-77. Acta Vet Hung. 1994. PMID: 7810409 Review.
-
An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine.Vaccine. 2004 Jun 2;22(17-18):2129-36. doi: 10.1016/j.vaccine.2003.12.005. Vaccine. 2004. PMID: 15149769 Clinical Trial.
-
Genetic engineering of the pseudorabies virus genome to construct live vaccines.J Reprod Fertil Suppl. 1990;41:97-104. J Reprod Fertil Suppl. 1990. PMID: 2170641
-
Characterization of a quadruple glycoprotein-deleted pseudorabies virus mutant for use as a biologically safe live virus vaccine.J Gen Virol. 1994 Jul;75 ( Pt 7):1723-33. doi: 10.1099/0022-1317-75-7-1723. J Gen Virol. 1994. PMID: 8021601
-
Vaccines against pseudorabies virus (PrV).Vet Microbiol. 2017 Jul;206:3-9. doi: 10.1016/j.vetmic.2016.11.019. Epub 2016 Nov 18. Vet Microbiol. 2017. PMID: 27890448 Review.
Cited by
-
Same Dosages of rPRV/XJ5-gI-/gE-/TK- Prototype Vaccine or Bartha-K61 Vaccine Similarly Protects Growing Pigs Against Lethal Challenge of Emerging vPRV/XJ-5 Strain.Front Vet Sci. 2022 Jul 1;9:896689. doi: 10.3389/fvets.2022.896689. eCollection 2022. Front Vet Sci. 2022. PMID: 35847653 Free PMC article.